{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"PR: greater than or equal to (≥) 50 percent (%) decrease in the contrast-enhancing lesion seen on MRI as compared with the baseline images; (2) Corticosteroid dose was irrelevant to the determination of PR; for participants with ocular disease, ophthalmologic exam must show a decrease in vitreous cell count or retina/optic nerve cellular infiltrate but may have continued to show persistent malignant or suspicious cells; for participants with CSF positive for neoplastic cells, CSF cytology may be negative or continue to show persistent malignant or suspicious cells in patients with ≥50% decrease in the primary brain lesions; no new sites of disease.","groups":[{"description":"Participants received single doses of rituximab 750 mg/m\\^2 IV at Weeks 1 through 5, and 7, 9, 11, 14, 16, 18, 20, and 22; cytarabine 2 g/m\\^2 IV every 24 hours for 2 doses at Weeks 11 and 22; and single doses of MTX 8 g/m\\^2 IV at Weeks 3, 5, 7, 9, 14, 16, 18, and 20.","id":"OG000","title":"Rituximab, Cytarabine, and MTX"}],"populationDescription":"Due to early study termination, all efficacy data were documented by data listings only, no data analysis was performed.","reportingStatus":"POSTED","timeFrame":"Week 24","title":"Percentage of Participants With a CR, CRu or Partial Response (PR)","type":"PRIMARY"}